1. Home
  2. ALAR vs CMMB Comparison

ALAR vs CMMB Comparison

Compare ALAR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

N/A

Current Price

$1.67

Market Cap

13.3M

Sector

Technology

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$2.34

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALAR
CMMB
Founded
2013
2004
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
13.8M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
ALAR
CMMB
Price
$1.67
$2.34
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$14.00
$25.00
AVG Volume (30 Days)
108.3K
64.0K
Earning Date
05-28-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
$24.51
N/A
Revenue Next Year
$33.43
N/A
P/E Ratio
$44.31
$54.25
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$1.35
52 Week High
$18.00
$3.78

Technical Indicators

Market Signals
Indicator
ALAR
CMMB
Relative Strength Index (RSI) 24.64 N/A
Support Level $1.62 N/A
Resistance Level $2.10 N/A
Average True Range (ATR) 0.09 0.00
MACD 0.14 0.00
Stochastic Oscillator 9.09 0.00

Price Performance

Historical Comparison
ALAR
CMMB

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: